Biotech company, Opthea (ASX:OPT) has successfully dosed the first patients in Australia as part of its Phase 2a clinical study.
The company will conduct a study of its OPT-302 treatment for diabetic macular edema.
The trial will evaluate whether patients will benefit from the addition of the treatment to their current regime.
Dr Megan Baldwin , CEO and Managing Doirector of Opthea says the involvement of the Australian clinical trial sites in the study further expands the international geographical reach of the clinical research program.
Shares in Opthea (ASX:OPT) closed 7.69 per cent higher to 63 cents on Friday